Pyrimidine catabolism
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Loading Image
Here is a detailed account of pyrimidine catabolism, sourced from Harper's Illustrated Biochemistry (32nd ed.) and Basic Medical Biochemistry (6th ed.).
Pyrimidine Catabolism
Key Contrast with Purine Catabolism
Purine catabolism ends in uric acid, which is sparingly soluble and can precipitate in joints (gout) or renal tubules. Pyrimidine catabolism is entirely different - the end products (CO2, NH3, β-alanine, and β-aminoisobutyrate) are highly water-soluble and easily excreted. This is why disorders of pyrimidine catabolism cause far fewer clinical problems than disorders of purine catabolism.
The Three-Step Pathway
All three pyrimidine bases (cytosine, uracil, thymine) are degraded through the same sequence of three enzymatic reactions. Cytosine is first deaminated to uracil, so both converge on uracil before degradation.
Step 1 - Reduction (Ring Saturation)
Enzyme: Dihydropyrimidine dehydrogenase (DPD, EC 1.3.1.2)
Cofactor: NADPH
- Uracil → Dihydrouracil
- Thymine → Dihydrothymine
The 5,6-double bond of the pyrimidine ring is reduced. This is the rate-limiting step of pyrimidine catabolism.
Step 2 - Ring Opening (Hydrolysis)
Enzyme: Dihydropyrimidinase (EC 3.5.2.2)
- Dihydrouracil + H2O → β-Ureidopropionate (N-carbamoyl-β-alanine)
- Dihydrothymine + H2O → β-Ureidoisobutyrate (N-carbamoyl-β-aminoisobutyrate)
The pyrimidine ring is cleaved hydrolytically, yielding linear ureido-compounds.
Step 3 - Final Hydrolysis
Enzyme: β-Ureidopropionase (hepatic, EC 3.5.1.6) - this single enzyme handles both substrates
- β-Ureidopropionate → β-Alanine + CO2 + NH3
- β-Ureidoisobutyrate → β-Aminoisobutyrate + CO2 + NH3
The figure below illustrates the full pathway:
Fate of End Products
| End Product | Source | Fate |
|---|---|---|
| β-Alanine | Uracil (and cytosine via uracil) | Excreted in urine; or transaminated to malonate semialdehyde → acetyl-CoA |
| β-Aminoisobutyrate | Thymine | Excreted in urine; or converted to succinyl-CoA (enters TCA cycle) |
| CO2 | Both pathways | Exhaled |
| NH3 | Both pathways | Enters urea cycle |
Note: Increased urinary β-aminoisobutyrate is seen in leukemia and after severe x-ray radiation, due to accelerated DNA destruction. It is also a normal ethnic variant - many persons of Chinese or Japanese ancestry routinely excrete higher amounts.
Pseudouridine - The Exception
Pseudouridine (ψ), derived from RNA degradation, has an unusual C-glycosidic bond. No human enzyme can hydrolyze or phosphorolyze it. It is therefore excreted unchanged in the urine - it was first isolated from human urine.
Clinical Disorders of Pyrimidine Catabolism
Because the end products are water-soluble, overproduction of pyrimidines rarely causes clinical signs. Exceptions arise from enzyme deficiencies:
1. Dihydropyrimidine Dehydrogenase (DPD) Deficiency
- Also called β-hydroxybutyric aciduria or combined uraciluria-thyminuria
- Genetic form: autosomal recessive; causes serious neurological complications (developmental delay, autistic features, seizures - as described in Bradley and Daroff's Neurology in Clinical Practice)
- Because DPD is blocked, both uracil and thymine accumulate and are excreted in urine
- This is simultaneously a disorder of β-amino acid biosynthesis, since β-alanine and β-aminoisobutyrate cannot be formed
- Critical pharmacological implication: 5-fluorouracil (5-FU), the anticancer drug, is a fluorinated uracil analog that is normally detoxified by DPD. Patients with low DPD levels (genetic or otherwise) who receive 5-FU suffer severe, potentially fatal 5-FU toxicity (mucositis, myelosuppression, neurotoxicity)
2. Dihydropyrimidinase Deficiency
- Second enzyme in the pathway (ring opening step)
- Also associated with severe 5-FU toxicity in cancer patients
- Neurological complications including autistic features
3. β-Ureidopropionase Deficiency
- Third enzyme; impairs the final hydrolysis step
- Similarly associated with severe 5-FU toxicity
Summary Table (from Harper's Table 33-1)
| Defective Enzyme | Key Signs |
|---|---|
| Dihydropyrimidine dehydrogenase | β-hydroxybutyric aciduria, uraciluria-thyminuria, neurological disease, severe 5-FU toxicity |
| Dihydropyrimidinase | Neurological disease, severe 5-FU toxicity |
| β-Ureidopropionase | β-amino acid deficiency, severe 5-FU toxicity |
Overproduction Scenarios
Since pyrimidine catabolites are water-soluble, overproduction itself is not clinically significant. However, related conditions cause pyrimidine precursor excretion:
- Hyperuricemia with PRPP overproduction - excess PRPP drives both purine AND pyrimidine synthesis, increasing β-alanine excretion
- Ornithine transcarbamoylase (OTC) deficiency - excess carbamoyl phosphate exits mitochondria into the cytosol and drives pyrimidine biosynthesis, causing orotic aciduria + uraciluria + uridinuria
- Allopurinol / 6-azauridine - both drugs can precipitate orotic aciduria by inhibiting orotidylate decarboxylase in pyrimidine biosynthesis
- Reye syndrome - damaged mitochondria cannot use carbamoyl phosphate, which spills into the cytosol and drives orotic acid overproduction
Sources:
- Harper's Illustrated Biochemistry, 32nd Ed., pp. 349, 357-358 (Figure 33-12)
- Basic Medical Biochemistry: A Clinical Approach, 6th Ed., Chapter 39
- Bradley and Daroff's Neurology in Clinical Practice - dihydropyrimidine dehydrogenase deficiency section
Pyrimidine degradation flowchart photo
Generating Image
Pyrimidine degradation flowchart showing: Cytosine being deaminated to Uracil (releasing NH3), and Thymine on a parallel track. Step 1: Both Uracil and Thymine reduced by Dihydropyrimidine dehydrogenase (DPD) using NADPH to form Dihydrouracil and Dihydrothymine respectively. Step 2: Ring opening by Dihydropyrimidinase with H2O to form beta-Ureidopropionate (N-carbamoyl-beta-alanine) from Dihydrouracil, and beta-Ureidoisobutyrate (N-carbamoyl-beta-aminoisobutyrate) from Dihydrothymine. Step 3: Final hydrolysis by beta-Ureidopropionase releasing CO2 and NH3, producing beta-Alanine from the uracil pathway and beta-Aminoisobutyrate from the thymine pathway. Clean educational biochemistry diagram with two parallel columns, arrows, enzyme names in boxes, cofactors labeled, and final products highlighted.
Here is a summary of what the flowchart shows:
Cytosine track:
Cytosine → (deamination, releases NH3) → Uracil
Two parallel tracks from there:
| Step | Uracil Track | Thymine Track |
|---|---|---|
| 1 - Reduction | Uracil + NADPH → Dihydrouracil | Thymine + NADPH → Dihydrothymine |
| Enzyme | Dihydropyrimidine dehydrogenase (DPD) | Same enzyme |
| 2 - Ring opening | Dihydrouracil + H2O → β-Ureidopropionate | Dihydrothymine + H2O → β-Ureidoisobutyrate |
| Enzyme | Dihydropyrimidinase | Same enzyme |
| 3 - Final hydrolysis | β-Ureidopropionate → β-Alanine + CO2 + NH3 | β-Ureidoisobutyrate → β-Aminoisobutyrate + CO2 + NH3 |
| Enzyme | β-Ureidopropionase | Same enzyme |
All end products are highly water-soluble - unlike uric acid from purine catabolism.
This is a shared conversation. Sign in to Orris to start your own chat.